hit counter
ChemoCentryx, Inc. (CCXI) Stock News Sentiment & Price - Sentifly
CCXI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ChemoCentryx, Inc. (CCXI)

USA
Biotechnology
NASDAQ
CCXI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CCXI Latest news
The Motley Fool
Positive
Is It Too Late to Buy ChemoCentryx Stock?
2021-10-14 07:18

The stock surged after obtaining FDA approval for avacopan.

Business Wire
Neutral
Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense TAVNEOS™ (avacopan), an Adjunctive Treatment for ANCA-Associated Vasculitis
2021-10-13 10:43

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces that it will begin dispensing TAVNEOS™ (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis), in combination with standard therapy. TAVNEOS™ is manufactured by California-based ChemoCentryx, Inc., a biopharma company focus

The Motley Fool
Positive
2 Super-Charged Growth Stocks to Buy Now
2021-10-13 10:00

These two small drugmakers are poised for a long-winded growth spurt.

Benzinga
Neutral
BZ Chart Of The Day: ChemoCentryx
2021-10-11 11:43

There's an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ:CCXI).

Pulse2
Positive
CCXI Stock: Why It Increased Today
2021-10-11 10:17

The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 9% during intraday trading today. This is why it happened.

GlobeNewsWire
Neutral
ChemoCentryx Appoints Rita I. Jain, M.D.
2021-10-11 08:30

Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product

The Motley Fool
Positive
Why ChemoCentryx Stock Skyrocketed Today
2021-10-08 17:40

Investors are excited about the biotech's game-changing new drug.

Invezz
Positive
Should you buy ChemoCentryx stock as shares spike 70% on avacopan approval?
2021-10-08 16:30

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an orally administered small-molecule C5a receptor antagonist, which selectively blocks the effects of C5a through the C5a receptor.

Zacks Investment Research
Positive
ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis
2021-10-08 13:27

The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval.

The Motley Fool
Neutral
ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
2021-10-08 13:10

The broader market was mixed on Friday.

Loading more news...